Edge Therapeutics’ EG-1962 Secures FDA Fast Track Status

Edge Therapeutics has secured FDA fast track status for EG-1962, its candidate for the treatment of subarachnoid hemorrhage, which is also known as a ruptured brain aneurysm.

The company expects to begin enrolling patients in clinical trials in the next couple of months to evaluate the efficacy and safety of the candidate versus oral nimodipine. Patients will be enrolled in North America, Europe, Israel and Australasia.